Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sign Informed Consent.~* 21 years of age or older.~* Able to follow instructions and willing to attend required study visits.~* Clinical diagnosis of ocular hypertension, primary open-angle, or pigment dispersion glaucoma in at least one eye (qualifying eye).~* Intra-ocular pressure (IOP) considered to be safe in both eyes in such a way that should assure clinical stability of vision and the optic nerve throughout the trial.~* Must have best corrected visual acuity of 6/60 (6/60 Snellen, 1.0 LogMAR) or better in each eye.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Presence of other primary or secondary glaucomas not listed in inclusion criterion.~* Presence of corneal dystrophies.~* Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.~* Intraocular conventional surgery or laser surgery in qualifying eye(s) less than three months prior to Visit 1.~* Risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's best judgment.~* Women of childbearing potential not using reliable means of birth control.~* Women who are pregnant or lactating.~* Participation in any other investigational study within 30 days prior to Visit 1.~* Current or anticipated use of systemic corticosteroids, by any route except inhaled, for greater than two weeks during the trial.~* Severe allergic rhinitis~* History of ocular herpes simplex.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brinzolamide/Timolol Maleate Fixed Combination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).